Annual General Meeting of Gerresheimer AG approves dividend of EUR 0.70 per share

- Dividend raised to EUR 0.70 per share
- Management Board and Supervisory Board given formal approval by large majority
- Dr. Axel Herberg new member of the Supervisory Board for shareholders

Duesseldorf, April 30, 2014 – A dividend of EUR 0.70 per share was approved at the Annual General Meeting of Gerresheimer AG held today in Duesseldorf. The Company, a leading partner to the pharma and healthcare industry, presented a strong set of results for financial year 2013.

“2013 was a good year for Gerresheimer AG. We achieved all the goals we set ourselves and sharpened our organization’s customer focus, thereby taking important steps in setting a course for the future. For 2014, we are counting on further growth in industrialized and emerging economies. We thus plan to further extend our leading position as global partner to the pharma and healthcare industry,” said Uwe Röhrhoff, CEO of Gerresheimer AG, summarizing the strategy at the Annual General Meeting.

The dividend of EUR 0.70 per entitled no-par-value share will be paid out on May 2, 2014. In the prior year, a dividend of EUR 0.65 per share was distributed.

The actions of the Management Board and Supervisory Board in financial year 2013 were approved by a large majority. Dr. Axel Herberg, Senior Managing Director of The Blackstone Group Germany GmbH, was voted in by a large majority at the Annual General Meeting as a new member of the Supervisory Board for shareholders. Amendments to the Articles of Association in relation to Supervisory Board remuneration were likewise passed by a large majority. The Annual General Meeting also approved amendment agreements to the Profit and Loss Transfer Agreement with Gerresheimer Holdings GmbH and a Domination Agreement with Gerresheimer Holdings GmbH. Deloitte & Touche GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was appointed as auditor for financial year 2014.
71.79% of the capital stock was represented at today’s Annual General Meeting. The results of the voting on all items of the agenda at the Annual General Meeting can be viewed at: www.gerresheimer.com/en/investor-relations/annual-general-meeting/annual-general-meeting-2014

The speech delivered at the Annual General Meeting is available here: www.gerresheimer.com/en/investor-relations/annual-general-meeting/annual-general-meeting-2014

The online version of the Annual Report 2013 is available here: http://annualreport2013.gerresheimer.com

About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products the company contributes to health and well-being. Gerresheimer has worldwide operations and its 11,000 employees manufacture products in local markets, close to its customers. With over 40 plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of approximately EUR 1.2 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe and simple administration of medicines: Insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Media Contact
Jens Kürten
Director Corporate Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com

Investor Relations & Creditor Relations Contact
Anke Linnartz
Director Corporate Investor Relations & Creditor Relations
Phone +49 211 6181-314
Fax +49 211 6181-121
E-Mail a.linnartz@gerresheimer.com